|
Combination Therapy to Overcome Resistance to Platinum-Based Chemotherapy
Application
MAST1 inhibitors to overcome resistance to platinum-based chemotherapy, exacerbated by dexamethasone co-administration.
Key Benefits
Co-administration of MAST1 inhibitor and MAST1-stabilizing protein inhibitor abrogates tumor resistance to cisplatin
MAST1 inhibitor, lestaurtinib, has previously reached phase III clinical trials and...
Published: 7/28/2023
Contributor(s): Sumin Kang, Jing Chen
|
|
Glycolysis Inhibitors as Potential Cancer Therapeutics
Application
A new potential anti-cancer agent that inhibits the glycolytic enzyme PGAM1 and thereby tumor growth.
Key Benefits
Targets tumor metabolism by inhibiting glycolytic enzyme and turning off tumor metabolism.
Inhibition of glycolytic enzyme (PGAM1) by these inhibitors leads to significant reduction in tumor growth.
Market Summary
There...
Published: 4/23/2024
Contributor(s): Jing Chen, Taro Hitosugi, Sumin Kang
|
|
Cancer Cell Metabolism Inhibitors for Targeted Therapies
Application
Glutamate dehydrogenase (GDH1) inhibitors targeting cancer cell metabolic pathways.
Key Benefits
Targets tricarboxylic acid (TCA) cycle/mitochondrial metabolism utilized by several cancer cell types for cell growth and survival.
Reduces cell proliferation and viability in several tumor derived cell lines as well as in xenograft tumor...
Published: 4/23/2024
Contributor(s): Sumin Kang, Jing Chen, Lingtao Jin
|
|
DHAA and Derivatives for Treatment of BRAF-V600E-Positive Cancer
Application
Hypolipidemic dehydroacetic acid (DHAA) treatment to prevent growth of BRAF V600E positive tumors.
Key Benefits
Treatment with slows BRAF V600E-positive tumor growth.
Repurposed compound may speed FDA approval.
May be used in combination with other therapies.
Market Summary
Up to 50% of melanoma cases harbor the BRAF V600E mutation,...
Published: 4/23/2024
Contributor(s): Jing Chen, Jack Arbiser, Brian Pollack, Siyuan Xia
|